US2014256801A1PendingUtilityA1
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
Est. expiryOct 28, 2024(expired)· nominal 20-yr term from priority
A61P 25/04C12Y 401/01015C12N 15/86C12N 2840/20C12N 9/88C12N 2710/16643C07K 14/435C12N 15/64C12N 15/09
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides a method of treating spinal cord injury pain or peripheral neuropathic pain in a mammal comprising administering to a mammal a vector comprising a nucleotide sequence encoding a glutamic acid decarboxylase (GAD) protein in an amount effective to treat spinal cord injury pain or peripheral neuropathic pain.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . A method of treating spinal cord injury pain or peripheral neuropathic pain in a mammal comprising: administering to a mammal experiencing spinal cord injury pain or peripheral neuropathic pain a vector comprising a nucleotide sequence encoding a glutamic acid decarboxylase (GAD) protein in an amount effective to treat spinal cord injury pain or peripheral neuropathic pain.
14 . The method of claim 13 , wherein the vector is a viral vector.
15 . (canceled)
16 . (canceled)
17 . The method of claim 13 , wherein the vector is a non-viral vector.
18 . The method of claim 13 , wherein the GAD protein is GAD67.
19 . The method of claim 13 , wherein the nucleotide sequence encoding the GAD protein is operably linked to a promoter.
20 . The method of claim 19 , wherein the promoter is a human cytomegalovirus immediate early promoter (HCMV IEp).
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . The method of claim 13 , wherein the vector is peripherally administered.
27 . The method of claim 26 , wherein the vector is administered to an appendage.
28 . The method of claim 27 , wherein the appendage is below a level of spinal cord injury.
29 . The method of claim 13 , wherein the mammal is a human.
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . The method of claim 13 , wherein the GAD protein is GAD25.
40 . The method of claim 13 , wherein the GAD protein is GAD65.
41 . The method of claim 14 , wherein the viral vector is a retroviral vector.
42 . The method of claim 14 , wherein the viral vector is a parvovirus based vector.
43 . The method of claim 14 , wherein the viral vector is an adeno-associated virus (AAV) based vector.
44 . The method of claim 14 , wherein the viral vector is an adenovirus-based vector.
45 . The method of claim 14 , wherein the viral vector is a chimeric viral vector.
46 . The method of claim 14 , wherein the viral vector is a herpes virus based vector.
47 . The method of claim 46 , wherein the herpes virus based vector is a non-amplicon herpes simplex virus (HSV) based vector.
48 . The method of claim 47 , wherein the vector is deficient for at least one essential HSV gene.
49 . The method of claim 48 , wherein the essential HSV gene is an early, immediate-early, or late HSV gene.
50 . The method of claim 49 , wherein the vector is deficient for an immediate early gene is selected from the group consisting of: ICP4, ICP22, ICP27, ICP47, and a combination thereof.
51 . The method of claim 47 , wherein the vector comprises extended deletions of ICP4, ICP27, and the deletion of UL55.
52 . The method of claim 47 , wherein the vector is replication deficient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.